Alzheimer's Drug Discovery Foundation

We're thrilled to announce Daniel Skovronsky of Eli Lilly and Company is the recipient of the 2025 Melvin R. Goodes Prize! Skovronsky will be recognized for his groundbreaking work developing critical diagnostic tests for Alzheimer’s in addition to his leadership in developing and commercializing Kisunla, one of the first disease-modifying therapies for Alzheimer’s patients. The Goodes Prize, referred to as the Nobel Prize of Alzheimer’s research, is presented annually to a leading scientist to mark exceptional contributions to the Alzheimer’s field. This international award was established by the late Melvin R. Goodes to advance critical science aimed at fighting Alzheimer’s disease and related dementias. The award will be presented at the ADDF's Inaugural Scientific Summit on March 5th: https://prn.to/434lJxO. Please join us in congratulating Daniel Skovronsky on this momentous achievement!

Congratulations Alzheimer's Drug Discovery Foundation's #Diagnostics Accelerator team for publishing this position paper on #ocular biomarkers for early detection. Here are the key takeaways: - Blood-based testing is expected to become the primary method for differential diagnosis of AD. - Ocular testing offers a non-invasive alternative to identify pre-clinical individuals in different settings (i.e., optometry and ophthalmology clinics) - Ocular technologies have yet to achieve the necessary standards for widespread adoption as an #Alzheimers disease screening tool. Why do they say this? Ocular technologies must meet the technical requirements (e.g., 90%–95% sensitivity, 75%–85% specificity) for pre-clinical AD screening and be comparable to blood-based tests. Congrats and thank you, Nikhil Dave Aishu Sukumar Eli Shobin Melissa Lee, PhD Sam Ulin Kim Goh. https://lnkd.in/gEBn_dEa Can we meet this challenge? This is a great call to action.

🌿 Exciting news! We’re renewing our partnership with the Alzheimer's Drug Discovery Foundation (ADDF) to support groundbreaking research and raise awareness about the connection between nutrition and cognitive health.   A recent NJBIZ article highlights our commitment to health and wellness education, including our continued sponsorship of ADDF events and in-store initiatives to spread their important mission. Research increasingly suggests that olive oil can play a role in brain health, and we are proud to be part of this conversation.   Beyond this partnership, we also are deepening our 35-year relationship with Culinary Careers Program (C•CAP) to launch an olive oil-focused curriculum for culinary students across the U.S. Our goal? To inspire the next generation of chefs and home cooks to embrace olive oil as a nutritious, flavorful staple in their kitchens.   We believe in using food as a force for good—whether it’s promoting a healthier future or creating opportunities for the next generation of culinary professionals.   🔗 Read the full NJBIZ article here: https://lnkd.in/g5qzPZ8Z

There has been a lot in the media the last few weeks taking a backwards look at Alzheimer’s science. The amyloid debate has long been settled but for some reason continues to get play. Wasted in the dialogue has been a clear picture on what truly is going on today. Nice to see the attached from Pharma Boardroom providing the real view on where we are and where we are going.

🚨 We're hiring! 🚨 We’re excited to announce that we are searching for a Major Gifts Officer to join our team! This is a fantastic opportunity for a dynamic fundraising professional to make a meaningful impact. If you or someone you know is passionate about building relationships and securing major gifts, we’d love to hear from you. #Hiring #MajorGiftsOfficer #FundraisingJobs📌 Apply here: https://lnkd.in/esEAJPr2 

The next era of Alzheimer’s treatments and diagnostics is here. One week from now, on Wednesday January 29th, the ADDF will bring together a distinguished panel of experts with Endpoints News for an engaging discussion titled, “What’s on the Horizon: The Next Era of Alzheimer’s Treatments and Diagnostics.” Key topics include: novel advances in diagnostics and biomarkers, new approaches for drug development focused on combination therapies, and strategies for shaping the future of Alzheimer’s research. Register now to join us: https://bit.ly/3PpyMly.

Congratulations to Beckman Coulter Diagnostics and ALZpath Inc. on this exciting milestone! The launch of Beckman’s new ptau217 assay, now available for research use, marks a significant step forward in the study of neurodegenerative diseases, particularly Alzheimer’s. By incorporating the ALZpath antibody, this assay will offer valuable insights into p-Tau217, GFAP, NfL, and APOE ε4 biomarkers, which are critical to advancing our understanding of Alzheimer’s and related conditions. This development holds great promise for accelerating research and ultimately improving diagnostics and new approaches to treatments.

ADDF’s CFO Karen Bettauer Harris recently shared her reflections on #JPM2025, noting the growing importance of novel biomarkers and combination therapies in Alzheimer’s care. To continue this important discussion, we’re hosting a webinar moderated by Sy Mukherjee with leading experts, including Laurence Barker from SV Health Investors' Dementia Discovery Fund (DDF), our very own Howard Fillit, MD, Christian Howell from Cognito Therapeutics, Inc., Michelle Mielke from Wake Forest University School of Medicine and Laura Steele from Eli Lilly and Company, who will share their perspectives on the future of Alzheimer’s treatments and diagnostics. Register here: https://bit.ly/3PpyMly.

Great discussion this morning on #Alzheimers disease at Biotech Showcase with our CEO Christian Howell. Panel was moderated by Karen Harris at Alzheimer's Drug Discovery Foundation, and also featured Maha Radhakrishnan from Sofinnova Investments , Abraham (Abe) C. CEO at Rapport Therapeutics and Olga Danilchanka from MRL Ventures Fund LLC.

Innovations in Alzheimer's treatments continue with the FDA's announcement that they have accepted Eisai US and Biogen's application for the subcutaneous application of Leqembi for weekly maintenance dosing. If approved, this would be the first Alzheimer's drug available for at home delivery, marking a significant step for patients and their families: https://bit.ly/42d0Y2M. Congratulations to our partners at Eisai and Biogen on this exciting milestone!